

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended

To
THE BOARD OF DIRECTORS
MEDICO REMEDIES LIMITED

We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") for the quarter ended 30th June, 2025 together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 8th August, 2025 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

UDIN: 25164370BMIEKL9268

For V J SHAH & CO,
Chartered Accountants
Firm Registration No.: 109823W



CHINTAN V SHAH
Partner
Membership Number: 164370



Place: Mumbai
Date: 8th August, 2025

MEDICO REMEDIES LIMITED
CIN: L24230MH1994PLC077187
Statement of Unaudited Standalone Financial Results for the quarter ended on June 30, 2025

Sn	Particulars	Quarter ended			For the Year Ended
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	INCOME				
	(a) Revenue from Operations	3,825.15	4,130.33	3,079.81	15,094.06
	(b) Other Income	65.81	29.30	29.32	268.94
	Total Income (a+b)	3,890.96	4,159.62	3,109.13	15,363.00
2	Expenses				
	(a) Cost of raw materials consumed	2,870.91	2,941.66	2,255.35	11,139.04
	(b) Purchase of traded goods	62.46	55.86	52.34	209.69
	(c) Changes in inventories of finished goods, work-in progress and traded goods	-199.51	-261.08	-102.14	-515.77
	(d) Employee Benefits Expense	170.36	158.15	144.17	627.65
	(e) Finance Costs	28.11	49.40	17.65	115.85
	(f) Depreciation and Amortisation Expense	76.90	76.56	75.22	303.01
	(g) Other Expenses	638.33	569.21	449.02	2,133.16
	Total expenses	3,647.55	3,589.76	2,891.61	14,012.63
3	Profit/(Loss) before Tax (1-2)	243.42	569.86	217.52	1,350.37
4	Income Tax expenses				
	a) Current Tax	53.58	187.70	53.40	380.24
	b) Deferred Tax [(charge/(credit)]	8.01	-51.93	6.23	-39.19
	Total Tax Expenses	61.58	135.77	59.63	341.05
5	Profit/(Loss) for the period (3-4)	181.83	434.09	157.89	1,009.32
6	Other comprehensive income not to be reclassified to Profit and Loss in subsequent periods				
	Profit and Loss in subsequent periods				
	Re-measurement gain/(losses) on defined benefit Plans	0.16	-0.27	0.30	0.63
	Tax effect [(charge)/credit]	-0.04	0.07	-0.08	-0.16
	Other comprehensive income/(loss) (net of tax)	0.12	-0.20	0.22	0.47
7	Total comprehensive income/(loss) for the period (5+6)	181.95	433.88	158.12	1,009.79
8	Paid-up equity share capital(Face value per share: Re.2/-) (No.in lakhs)	829.84	829.84	829.84	829.84
9	Other Equity excluding revaluation reserve as per the audited balance sheet				4,587.21
10	Earning per Equity Share of face value of Re.2/- each (Not Annualised)				
	Basic EPS (in Rs.)	0.22	0.52	0.19	1.22
	Diluted EPS (in Rs.)	0.22	0.52	0.19	1.22

For Medico Remedies Limited

H Mehta

Haresh Mehta
Chairman and Whole Time Director
DIN:01080289

For Medico Remedies Limited

H Mehta

Harshit Mehta
Managing Director
DIN: 05144280



Notes:

1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on August 08, 2025 and subsequently approved by the Board of Directors at its meeting held on August 08, 2025. The review report has been filed with stock exchange and is available on the Company's website.
2. The figures for the quarter ended on 31st March 2025 are balancing figures between the audited figures for the year ended 31st March 2025 and reviewed year to date figures upto nine month ended 31st December 2024.
3. The standalone financial results for the quarter ended on 30th June, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company.
5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 "Operating Segments" notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below:

PARTICULARS	QE 30.06.2025	QE 31.03.2025
	Amount (Rs. In Lakh)	Amount (Rs. In Lakh)
1) Sales of products within India	539.65	628.52
2) Sales of products Outside India	3245.01	3457.77
Sub- Total	3784.66	4086.29

6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.
7. The company does not have any subsidiary/associate/joint venture company as on 30th June 2025.
8. The result for the quarter ended June 30, 2025 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.medicoremedies.com)

For and on behalf of the board,
For Medico Remedies Limited

Haresh Mehta

Haresh Mehta
Chairman and Whole Time Director
DIN:01080289



Harshit Mehta
Harshit Mehta
Managing Director
DIN:05144280

Place: Mumbai
Date: August 08, 2025

Place: Mumbai
Date: August 08, 2025